Literature DB >> 29110178

Priapism in a Fabry disease mouse model is associated with upregulated penile nNOS and eNOS expression.

Xing-Li Meng1, Erland Arning1, Mary Wight-Carter2, Taniqua S Day1, Siamak Jabbarzadeh-Tabrizi1, Shuyuan Chen3, Robin J Ziegler4, Teodoro Bottiglieri1, Jay W Schneider5, Seng H Cheng4, Raphael Schiffmann1, Jin-Song Shen6.   

Abstract

Fabry disease is a glycosphingolipidosis caused by deficient activity of α-galactosidase A; it is one of a few diseases that are associated with priapism, an abnormal prolonged erection of the penis. The goal of this study was to investigate the pathogenesis of Fabry disease-associated priapism in a mouse model of the disease. We found that Fabry mice develop late-onset priapism. Neuronal nitric oxide synthase (nNOS), which was predominantly present as the 120-kDa N-terminus-truncated form, was significantly upregulated in the penis of 18-month-old Fabry mice compared to wild type controls (~fivefold). Endothelial NOS (eNOS) was also upregulated (~twofold). NO level in penile tissues of Fabry mice was significantly higher than wild type controls at 18 months. Gene transfer-mediated enzyme replacement therapy reversed abnormal nNOS expression in the Fabry mouse penis. The penile nNOS level was restored by antiandrogen treatment, suggesting that hyperactive androgen receptor signaling in Fabry mice may contribute to nNOS upregulation. However, the phosphodiesterase-5A expression level and the adenosine content in the penis, which are known to play roles in the development of priapism in other etiologies, were unchanged in Fabry mice. In conclusion, these data suggested that increased nNOS (and probably eNOS) content and the consequential elevated NO production and high arterial blood flow in the penis may be the underlying mechanism of priapism in Fabry mice. Furthermore, in combination with previous findings, this study suggested that regulation of NOS expression is susceptible to α-galactosidase A deficiency, and this may represent a general pathogenic mechanism of Fabry vasculopathy.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29110178     DOI: 10.1007/s10545-017-0107-6

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  4 in total

Review 1.  Review of Ischemic and Non-ischemic Priapism.

Authors:  Mark G Biebel; Martin S Gross; Ricardo Munarriz
Journal:  Curr Urol Rep       Date:  2022-05-10       Impact factor: 3.092

Review 2.  Progress in the understanding and treatment of Fabry disease.

Authors:  James J Miller; Adam J Kanack; Nancy M Dahms
Journal:  Biochim Biophys Acta Gen Subj       Date:  2019-09-14       Impact factor: 3.770

3.  Dysregulated DNA methylation in the pathogenesis of Fabry disease.

Authors:  Jin-Song Shen; Uthra Balaji; Kunitoshi Shigeyasu; Yoshinaga Okugawa; Siamak Jabbarzadeh-Tabrizi; Taniqua S Day; Erland Arning; John Marshall; Seng H Cheng; Jinghua Gu; Raphael Schiffmann; Teodoro Bottiglieri; Ajay Goel
Journal:  Mol Genet Metab Rep       Date:  2022-09-26

Review 4.  Current and experimental therapeutics for Fabry disease.

Authors:  Vanessa Castelli; Cosimo Andrea Stamerra; Michele d'Angelo; Annamaria Cimini; Claudio Ferri
Journal:  Clin Genet       Date:  2021-05-25       Impact factor: 4.438

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.